What will be the role of molnupiravir in the treatment of COVID-19 infection?

Vitiello, Antonio; Troiano, Valentina; Porta, Raffaele La

doi:10.1007/s40267-021-00879-2

Cited by 18 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [2] Molnupiravir, being oral and also effective against newer COVID-19 variants, [8] is more practical and convenient for administration in ambulatory patients fulfilling the unmet need for safe and effective oral drugs in this population. [9] The huge reduction in the risk of mortality observed in our meta-analysis is highly encouraging. Future trials should evaluate the efficacy of molnupiravir in breakthrough infections as well as in comparison with other approved treatments for COVID-19.…”

mentioning

confidence: 55%

Efficacy and safety of molnupiravir for COVID-19 patients

Fatima

Azeem

Saeed

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

mentioning

confidence: 55%

Efficacy and safety of molnupiravir for COVID-19 patients

Fatima

Azeem

Saeed

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

“…Recently, in the UK the oral antiviral agent molnupiravir has been approved, a potent ribonucleoside analogue that inhibits the replication of SARS-CoV-2, acting on the enzyme that the virus uses to generate copies of itself by introducing errors into its genetic code. Furthermore, the data indicate that molnupiravir reduced the risk of hospitalization or death in approximately 50% of adults who were at risk of a severe disease outcome [65]. The molnupiravir was authorized for distribution in emergency conditions by a Decree of the Ministry of Health on 26 November 2021 and is indicated within 5 days of the onset of symptoms.…”

Section: Management Of Patients With Post-covid Syndrome and After Ef...mentioning

confidence: 99%

Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary sequelae after COVID-19 Infection

et al. 2022

View full text Add to dashboard Cite

Post-COVID syndrome or long COVID is defined as the persistence of symptoms after confirmed SARS-CoV-2 infection, the pathogen responsible for coronavirus disease. The content herein presented reviews the reported long-term consequences and aftereffects of COVID-19 infection and the potential strategies to adopt for their management. Recent studies have shown that severe forms of COVID-19 can progress into acute respiratory distress syndrome (ARDS), a predisposing factor of pulmonary fibrosis that can irreversibly compromise respiratory function. Considering that the most serious complications are observed in the airways, the inhalation delivery of drugs directly to the lungs should be preferred, since it allows to lower the dose and systemic side effects. Although further studies are needed to optimize these techniques, recent studies have also shown the importance of in vitro models to recreate the SARS-CoV-2 infection and study its sequelae. The information reported suggests the necessity to develop new inhalation therapies in order to improve the quality of life of patients who suffer from this condition.

show abstract

“…The EIDD-triphosphate form inhibits RNA replication of virus. Molnupiravir reduces the ability of SARS-CoV-2 to replicate in the body, producing alterations (mutations) of the genetic material (RNA) of the virus during replication, so as to make it unable to multiply an adverse event in the molnupiravir group compared with the placebo group (1.3% vs 3.4%) (Vitiello et al 2021). Results from a clinical trial showed that 35.4% and 43.8% of individuals reported adverse events after administration of molnupiravir and placebo, respectively.…”

Section: Molnupiravirmentioning

confidence: 99%

Pandemic COVID-19, an update of current status and new therapeutic strategies

Vitiello

Porta

Trama³

et al. 2022

Naunyn-Schmiedeberg's Arch Pharmacol

Self Cite

View full text Add to dashboard Cite

The global COVID-19 pandemic is underway. In recent weeks, several countries throughout the globe, and particularly in Europe, have experienced an exponential increase in the number of individuals infected with COVID-19, probably induced by a new variant of SARS-CoV-2, called the "Omicron variant." Mass vaccination against COVID-19 continues worldwide. Are authorized mRNA vaccines effective against the new Omicron variant? Recently, several pharmaceutical companies have developed oral antiviral pills against SARS-CoV-2, i.e., molnupiravir and paxlovid, that inhibit SARS-CoV-2 viral replication by acting on the RNA polymerase of SARS-CoV. In pre-registration clinical trials, molnupiravir and paxlovid have shown excellent clinical efficacy results, but what impact will these new oral antiviral agents have against pandemic COVID-19? In what specific clinical situations are they preferred over other antivirals such as remdesivir? In this brief review, we explore these important aspects.

show abstract

What will be the role of molnupiravir in the treatment of COVID-19 infection?

Cited by 18 publications

References 9 publications

Efficacy and safety of molnupiravir for COVID-19 patients

Efficacy and safety of molnupiravir for COVID-19 patients

Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary sequelae after COVID-19 Infection

Pandemic COVID-19, an update of current status and new therapeutic strategies

Contact Info

Product

Resources

About